Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2327 - Characterization and pre-clinical modeling of genetic aberrations in pediatric gliomas


28 Sep 2019


Poster Display session 1


Tumour Site

Central Nervous System Malignancies


Itai Moshe


Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243


I.P. Moshe1, O. Zohar1, B. Ismer2, L. Rousso-Noori1, D. Jones2, D. Friedmann- Morvinski1

Author affiliations

  • 1 Biochemistry And Molecular Biology, Faculty of Life Sciences Tel-Aviv University, 69978 - Tel Aviv/IL
  • 2 Pediatric Neurooncology, DKFZ, 69120 - Heidelberg/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2327


Gliomas are the most common CNS tumors in pediatric patients. Despite extensive efforts, the efficacy of the traditional treatments is limited and the overall prognosis is poor. Data from various studies have indicated a genetic diversity between Pediatric and adult gliomas that may imply for the need of dedicated therapeutic approaches for pediatric gliomas. Using whole-genome sequencing, we have identified a wide variety of genetic alterations in low-grade and high-grade pediatric glioma patients that were found to be of interest in terms of their pattern of occurrence and the availability of targeted inhibitors. These genetic aberrations include novel point mutations, gene fusions and duplications in oncogenic factors such as NTRK2 and FGFR1. In order to study the role of this mutated genes in pediatric glioma and to identify and pre-clinically test new therapeutic targets, in vivo models recapitulating the human disease are required.


In order to validate the role of the selected mutated genes in pediatric tumorigenesis we cloned these genetic aberrations into Cre-inducible lentiviral vectors and injected them directly into the brain of Cre transgenic post-natal 1 (PN1) pups. In vitro, we used the same lentiviral vectors to transduce embryonic neural stem cells to assess their transformation capacity.


We generated a series of novel pediatric glioma models with different combinations of oncogenes and tumor suppressor genes that leads to high mortality rate. Characterization of these tumors by immunofluorescence staining was consistent with common glioma markers. We also established primary cell lines from the generated tumors that are now being used for functional testing of specific inhibitors. In addition, we performed RNAseq analysis in order to assess the human relevance of these generated mouse models and to elucidate the mechanism of action of these mutations.


We were able to generate novel pediatric glioma mouse models that can be used to examine selected mutations found in human pediatric gliomas and serve as a pre-clinical tool for testing novel therapeutic targets.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


DKFZ-MOST grant.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.